RSS

Eli Lilly

Just after Alex Azar has been sworn in as the new Secretary of Health and Human Services under President Trump, many have been asking the question if he will be able to make good on his claim to prioritise the reduction of prescription drug costs more

News

Eli Lilly and digital health company Rimidi, have teamed up to create personalised solutions for people that use insulin to manage diabetes. more

News

Trump

GrAl / Shutterstock.com

US president, Donald Trump, has nominated Alex Azar — a former pharmaceutical executive — as his next health secretary. more

News

The US FDA has approved Verzenio (abemaciclib), from Eli Lilly and Company, for the treatment of adult patients who have HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. more

News

The UK Supreme Court (UKSC) has released its full judgment on the long running court case involving the product infringement of Eli Lilly and Company’s Alimta vitamin regimen patent — Actavis v Eli Lilly Case. more

News

Eli Lilly and Company has announced that the National Institute for Health and Care Excellence (NICE) has recommended olaratumab (Lartruvo▼) in combination with doxorubicin as a treatment for advanced soft tissue sarcoma in adults more

News

The collaboration between Eli Lilly and Company and KeyBioscience will focus on developing a potential new class of treatments for metabolic disorders, such as type 2 diabetes, called dual amylin calcitonin receptor agonists (DACRAs) more

News

Eli Lilly and Company, along with its partner Incyte, have seen a drop in the share prices after the FDA rejects its drug to treat rheumatoid arthritis (RA) — baricitinib. more

News

Eli Lilly and Company plans to invest $850 million in its US operations this year. These investments will span the company’s US facilities, including research laboratories, manufacturing sites and general and administrative areas. more

News

Pfizer, AstraZeneca, Merck and other Big Pharma companies have signed up to a consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s more

News

Last week we reported on Eli-Lilly’s breakthrough Alzheimer’s disease drug solanezumab. This week we look back at the history behind five existing treatments on the market. more

News

Following hot on the heels of yesterday’s announcement that Eli-Lilly’s drug solanezumab heralded a breakthrough in the treatment of Alzheimer’s, the EPM team has done some digging and presents four additional newsworthy developments in the field. more

News

A major breakthrough has been announced by Eli-Lilly in the fight against Alzheimer's. A trial of the pharma giant's drug solanezumab has shown a slowing down of the disease for patients in the early onset stages. more

News

An immunotherapy clinical trial collaboration is to be undertaken by Immunocore and Eli Lilly and Company, exploring the use of Immunocore’s lead T-cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (L more

News

After several months spent gaining approvals, the acquisition which sees Eli Lilly expand significantly has now completed. more

News

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. more

AZD3293 is an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. more

Participating companies are AstraZeneca, GSK, Janssen R&D, Lilly, Pfizer, Takeda and UCB. more

Change in management was observed in both patients who met and did not meet the appropriate use criteria. more

The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase its share of the diabetes treatment market more